NIH's Role In Sustaining the U.S. Economy 2021 Update Now Available here
UMR Urges House and Senate Leaders to Include NIH Funding in COVID Relief Package read here
UMR releases new fact sheets on COVID-19 and biomedical research. Read here
See how UMR members are aiding in the fight against the coronavirus here
A new episode of the Amazing Things Podcast is now available! Check it out here.

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

BD and CerTest Biotec Announce CE Mark for Molecular Test to Detect, Identify Certain SARS-CoV-2 Variants

ZARAGOZA, SPAIN and FRANKLIN LAKES, N.J. (Aug. 6, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec, today announced the CE mark for a molecular test that can detect and distinguish between the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) SARS-CoV-2 variants.

VIASURE SARS-CoV-2 Variant Real Time PCR Detection Kit for BD MAX™ can be used as a combined test with VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™, or as a reflex test to run variant identification on a SARS-CoV-2 positive sample.